TrialAntimicrobial agents and chemotherapy2014

SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.

Douglas Dieterich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.